LARIMAR THERAPEUTICS, INC. (LRMR) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -178.99M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 157.34M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-178.99M | (m) | (m) | $157.34M | (m) | (m) |
| 2026-03-31 | $-172.43M | (m) | (m) | $152.70M | (m) | (m) |
| 2025-12-31 | $-172.50M | (m) | (m) | $154.22M | (m) | (m) |
| 2025-09-30 | $-139.77M | (m) | (m) | $121.59M | (m) | (m) |
| 2025-06-30 | $-108.54M | (m) | (m) | $90.58M | (m) | (m) |
| 2025-03-31 | $-105.34M | (m) | (m) | $86.89M | (m) | (m) |
| 2024-12-31 | $-90.89M | (m) | (m) | $73.28M | (m) | (m) |
| 2024-09-30 | $-73.76M | (m) | (m) | $57.19M | (m) | (m) |
| 2024-06-30 | $-65.83M | (m) | (m) | $49.85M | (m) | (m) |
| 2024-03-31 | $-50.85M | (m) | (m) | $36.05M | (m) | (m) |
| 2023-12-31 | $-41.76M | (m) | (m) | $27.67M | (m) | (m) |
| 2023-09-30 | $-38.03M | (m) | (m) | $24.24M | (m) | (m) |
| 2023-06-30 | $-36.21M | (m) | (m) | $23.24M | (m) | (m) |
| 2023-03-31 | $-35.28M | (m) | (m) | $23.01M | (m) | (m) |
| 2022-12-31 | $-36.53M | (m) | (m) | $24.25M | (m) | (m) |
| 2022-09-30 | $-35.17M | (m) | (m) | $23.32M | (m) | (m) |
| 2022-06-30 | $-43.39M | (m) | (m) | $31.77M | (m) | (m) |
| 2022-03-31 | $-47.25M | (m) | (m) | $35.23M | (m) | (m) |
| 2021-12-31 | $-50.47M | (m) | (m) | $38.40M | (m) | (m) |
| 2021-09-30 | $-55.77M | (m) | (m) | $42.68M | (m) | (m) |
| 2021-06-30 | $-49.38M | (m) | (m) | $35.57M | (m) | (m) |
| 2021-03-31 | $-48.24M | (m) | (m) | $35.37M | (m) | (m) |
| 2020-12-31 | $-42.80M | (m) | (m) | $31.41M | (m) | (m) |
| 2020-09-30 | $-57.01M | (m) | (m) | $29.34M | (m) | (m) |
| 2020-06-30 | $-55.30M | (m) | (m) | $30.45M | (m) | (m) |
| 2020-03-31 | $-35.94M | $0.00 | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-45.65M | $0.00 | (m) | $23.89M | (m) | (m) |
| 2019-09-30 | $-53.06M | $0.00 | (m) | $34.92M | (m) | (m) |
| 2019-06-30 | $-55.33M | $0.00 | (m) | $41.49M | (m) | (m) |
| 2019-03-31 | $-58.70M | $0.00 | (m) | $45.13M | (m) | (m) |
| 2018-12-31 | $-61.12M | $0.00 | (m) | $47.93M | (m) | (m) |
| 2018-09-30 | $-59.79M | $0.00 | (m) | $47.38M | (m) | (m) |
| 2018-06-30 | $-57.46M | $0.00 | (m) | $45.28M | (m) | (m) |
| 2018-03-31 | $-55.44M | $0.00 | (m) | $43.59M | (m) | (m) |
| 2017-12-31 | $-53.00M | $0.00 | (m) | $40.84M | (m) | (m) |
| 2017-09-30 | $-50.12M | $0.00 | (m) | $37.20M | (m) | (m) |
| 2017-06-30 | $-52.11M | $0.00 | (m) | $37.48M | (m) | (m) |
| 2017-03-31 | $-53.63M | $0.00 | (m) | $37.12M | (m) | (m) |
| 2016-12-31 | $-58.23M | $0.00 | (m) | $39.94M | (m) | (m) |
| 2016-09-30 | $-71.00M | $0.00 | (m) | $50.37M | (m) | (m) |
| 2016-06-30 | $-75.88M | $0.00 | (m) | $54.54M | (m) | (m) |
| 2016-03-31 | $-78.43M | $0.00 | (m) | $56.90M | (m) | (m) |
| 2015-12-31 | $-73.81M | $0.00 | (m) | $54.62M | (m) | (m) |
| 2015-09-30 | $-61.23M | $0.00 | (m) | $44.26M | (m) | (m) |
| 2015-06-30 | $-55.88M | $0.00 | (m) | $42.16M | (m) | (m) |
| 2015-03-31 | $-44.25M | $0.00 | (m) | $34.33M | (m) | (m) |
| 2014-12-31 | $-35.53M | $0.00 | (m) | $27.39M | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-13.78M | $0.00 | (m) | $9.56M | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $-13.79M | $0.00 | (m) | $11.54M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |